Biomimetic proteolipid vesicles for targeting inflamed tissues
Source abstract
Abstract
A multitude of micro- and nanoparticles have been developed to improve the delivery of systemically administered pharmaceuticals, which are subject to a number of biological barriers that limit their optimal biodistribution. Bioinspired drug-delivery carriers formulated by bottom-up or top-down strategies have emerged as an alternative approach to evade the mononuclear phagocytic system and facilitate transport across the endothelial vessel wall. Here, we describe a method that leverages the advantages of bottom-up and top-down strategies to incorporate proteins derived from the leukocyte plasma membrane into lipid nanoparticles. The resulting proteolipid vesicles-which we refer to as leukosomes-retained the versatility and physicochemical properties typical of liposomal formulations, preferentially targeted inflamed vasculature, enabled the selective and effective delivery of dexamethasone to inflamed tissues, and reduced phlogosis in a localized model of inflammation.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Extracellular vesicles in disease · RNA Interference and Gene Delivery · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (50)
Show source-provided references
1. Torchilin, V. P. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nature Rev. Drug Discov. 13, 813–827 (2014).10.1038/nrd4333 ↗
2. Mitragotri, S., Burke, P. A. & Langer, R. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nature Rev. Drug Discov. 13, 655–672 (2014).10.1038/nrd4363 ↗
3. Tasciotti, E. et al. Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. Nature Nanotech. 3, 151–157 (2008).10.1038/nnano.2008.34 ↗
4. Parodi, A. et al. Bromelain surface modification increases the diffusion of silica nanoparticles in the tumor extracellular matrix. ACS Nano 8, 9874–9883 (2014).10.1021/nn502807n ↗
5. Mura, S., Nicolas, J. & Couvreur, P. Stimuli-responsive nanocarriers for drug delivery. Nature Mater. 12, 991–1003 (2013).10.1038/nmat3776 ↗
6. Kudgus, R. A. et al. Tuning pharmacokinetics and biodistribution of a targeted drug delivery system through incorporation of a passive targeting component. Sci. Rep. 4, 5669 (2014).10.1038/srep05669 ↗
7. Luk, B. T. & Zhang, L. Cell membrane-camouflaged nanoparticles for drug delivery. J. Control. Rel. 220, 600–607 (2015).10.1016/j.jconrel.2015.07.019 ↗
8. Hu, C.-M. J. et al. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc. Natl Acad. Sci. USA 108, 10980–10985 (2011).10.1073/pnas.1106634108 ↗
9. Hu, C.-M. J. et al. Nanoparticle biointerfacing by platelet membrane cloaking. Nature 526, 118–121 (2015).10.1038/nature15373 ↗
10. Parodi, A. Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. Nature Nanotech. 8, 61–68 (2013).10.1038/nnano.2012.212 ↗
11. Hammer, D. A. et al. Leuko-polymersomes. Faraday Discuss 139, 129–141 (2008).10.1039/b717821b ↗
12. Doshi, N. et al. Platelet mimetic particles for targeting thrombi in flowing blood. Adv. Mater. 24, 3864–3869 (2012).10.1002/adma.201200607 ↗
13. Blanco, E., Shen, H. & Ferrari, M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nature Biotechnol. 33, 941–951 (2015).10.1038/nbt.3330 ↗
14. Robbins, G. P. et al. Tunable leuko-polymersomes that adhere specifically to inflammatory markers. Langmuir 26, 14089–14096 (2010).10.1021/la1017032 ↗
15. Anselmo, A. C. et al. Platelet-like nanoparticles: mimicking shape, flexibility, and surface biology of platelets to target vascular injuries. ACS Nano 8, 11243–11253 (2014).10.1021/nn503732m ↗
16. Toledano Furman, N. E. et al. Reconstructed stem cell nanoghosts: a natural tumor targeting platform. Nano Lett. 13, 3248–3255 (2013).10.1021/nl401376w ↗
17. Yoo, J-W., Irvine, D. J., Discher, D. E. & Mitragotri, S. Bio-inspired, bioengineered and biomimetic drug delivery carriers. Nature Rev. Drug Discov. 10, 521–535 (2011).10.1038/nrd3499 ↗
18. Alvarez-Lorenzo, C. & Concheiro, A. Bioinspired drug delivery systems. Curr. Opin. Biotechnol. 24, 1167–1173 (2013).10.1016/j.copbio.2013.02.013 ↗
19. Gutiérrez Millán, C., Colino Gandarillas, C. I., Sayalero Marinero, M. L. & Lanao, J. M. Cell-based drug-delivery platforms. Ther. Deliver. 3, 25–41 (2012).10.4155/tde.11.141 ↗
20. Millan, C. G., Marinero, M. A. L. S., Castaneda, A. Z. & Lanao, J. M. Drug, enzyme and peptide delivery using erythrocytes as carriers. J. Control. Release 95, 27–49 (2004).10.1016/j.jconrel.2003.11.018 ↗
21. Bretscher, M. S. Asymmetrical lipid bilayer structure for biological membranes. Nature 236, 11–12 (1972).10.1038/236011a0 ↗
22. Demetzos, C. Differential scanning calorimetry (DSC): a tool to study the thermal behavior of lipid bilayers and liposomal stability. J. Liposome Res. 18, 159–173 (2008).10.1080/08982100802310261 ↗
23. Manconi, M. et al. Ex vivo skin delivery of diclofenac by transcutol containing liposomes and suggested mechanism of vesicle–skin interaction. Eur. J. Pharm. Biopharm. 78, 27–35 (2011).10.1016/j.ejpb.2010.12.010 ↗
24. Mura, S., Manconi, M., Sinico, C., Valenti, D. & Fadda, A. M. Penetration enhancer-containing vesicles (PEVs) as carriers for cutaneous delivery of minoxidil. Intl. J. Pharm. 380, 72–79 (2009).10.1016/j.ijpharm.2009.06.040 ↗
25. Chow, T. S. Nanoscale surface roughness and particle adhesion on structured substrates. Nanotechnology 18, 115713 (2007).10.1088/0957-4484/18/11/115713 ↗
26. Schaap, I. A., Eghiaian, F., des Georges, A. & Veigel, C. Effect of envelope proteins on the mechanical properties of influenza virus. J. Biol. Chem. 287, 41078–41088 (2012).10.1074/jbc.M112.412726 ↗
27. Mereghetti, P. et al. A Fourier transform infrared spectroscopy study of cell membrane domain modifications induced by docosahexaenoic acid. Biochim. Biophys. Acta 1840, 3115–3122 (2014).10.1016/j.bbagen.2014.07.003 ↗
28. Lodish, H. et al. Molecular Cell Biology (W. H. Freeman & Co., 2000).
29. Benmerah, A., Scott, M., Poupon, V. & Marullo, S. Nuclear functions for plasma membrane associated proteins? Traffic 4, 503–511 (2003).10.1034/j.1600-0854.2003.00102.x ↗
30. Durr, E. et al. Direct proteomic mapping of the lung microvascular endothelial cell surface in vivo and in cell culture. Nature Biotechnol. 22, 985–992 (2004).10.1038/nbt993 ↗
31. Lund, R., Leth-Larsen, R., Jensen, O. N. & Ditzel, H. J. Efficient isolation and quantitative proteomic analysis of cancer cell plasma membrane proteins for identification of metastasis-associated cell surface markers. J. Proteome Res. 8, 3078–3090 (2009).10.1021/pr801091k ↗
32. Liu, X., Zhang, M., Go, V. L. W. & Hu, S. Membrane proteomic analysis of pancreatic cancer cells. J. Biomed. Sci. 17, 74 (2010).10.1186/1423-0127-17-74 ↗
33. Corbo, C. et al. Proteomic profiling of a biomimetic drug delivery platform. Curr. Drug Targets 16, 1540–1547 (2015).10.2174/1389450115666141109211413 ↗
34. Zarbock, A., Ley, K., McEver, R. P. & Hidalgo, A. Leukocyte ligands for endothelial selectins: specialized glycoconjugates that mediate rolling and signaling under flow. Blood 118, 6743–6751 (2011).10.1182/blood-2011-07-343566 ↗
35. Soto Pantoja, D. R., Kaur, S., Miller, T. W., Isenberg, J. S. & Roberts, D. D. Leukocyte surface antigen CD47. UCSD Mol. Pages 2, http://dx.doi.org/10.6072/H0.MP.A005186.01 (2013).10.6072/H0.MP.A005186.01 ↗
36. Hu, C.-M. J. et al. ‘Marker-of-self’ functionalization of nanoscale particles through a top-down cellular membrane coating approach. Nanoscale 5, 2664–2668 (2013).10.1039/c3nr00015j ↗
37. Allen, T. Liposomal drug formulations. Drugs 56, 747–756 (1998).10.2165/00003495-199856050-00001 ↗
38. Cosco, D., Paolino, D., Cilurzo, F., Casale, F. & Fresta, M. Gemcitabine and tamoxifen-loaded liposomes as multidrug carriers for the treatment of breast cancer diseases. Intl. J. Pharm. 422, 229–237 (2012).10.1016/j.ijpharm.2011.10.056 ↗
39. Bernsdorff, C., Reszka, R. & Winter, R. Interaction of the anticancer agent Taxol TM (paclitaxel) with phospholipid bilayers. J. Biomed. Mater. Res. 46, 141–149 (1999).10.1002/(SICI)1097-4636(199908)46:2<141::AID-JBM2>3.0.CO;2-U ↗
40. Franchimont, D., Kino, T., Galon, J., Meduri, G. U. & Chrousos, G. Glucocorticoids and inflammation revisited: the state of the art. Neuroimmunomodulation 10, 247–260 (2002).10.1159/000069969 ↗
41. Gross, S. et al. Bioluminescence imaging of myeloperoxidase activity in vivo. Nature Med. 15, 455–461 (2009).10.1038/nm.1886 ↗
42. Azzopardi, E. A., Ferguson, E. L. & Thomas, D. W. The enhanced permeability retention effect: a new paradigm for drug targeting in infection. J. Antimicrob. Chemother. 68, 257–274 (2013).10.1093/jac/dks379 ↗
43. Ishibashi, M. et al. Integrin LFA-1 regulates cell adhesion via transient clutch formation. Biochem. Biophys. Res. Commun. 464, 459–466 (2015).10.1016/j.bbrc.2015.06.155 ↗
44. Arroyo, A. G. et al. Induction of tyrosine phosphorylation during ICAM-3 and LFA-1-mediated intercellular adhesion, and its regulation by the CD45 tyrosine phosphatase. J. Cell Biol. 126, 1277–1286 (1994).10.1083/jcb.126.5.1277 ↗
45. Sigal, A. et al. The LFA-1 integrin supports rolling adhesions on ICAM-1 under physiological shear flow in a permissive cellular environment. J. Immunol. 165, 442–452 (2000).10.4049/jimmunol.165.1.442 ↗
46. Lorenz, H. M. et al. CD45 mAb induces cell adhesion in peripheral blood mononuclear cells via lymphocyte function-associated antigen-1 (LFA-1) and intercellular cell adhesion molecule 1 (ICAM-1). Cell. Immunol. 147, 110–128 (1993).10.1006/cimm.1993.1052 ↗
47. Chen, X. et al. Inflamed leukocyte-mimetic nanoparticles for molecular imaging of inflammation. Biomaterials 32, 7651–7661 (2011).10.1016/j.biomaterials.2011.06.030 ↗
48. Sherman, M. B. et al. Removal of divalent cations induces structural transitions in red clover necrotic mosaic virus, revealing a potential mechanism for RNA release. J. Virol. 80, 10395–10406 (2006).10.1128/JVI.01137-06 ↗
49. Chiappini, C. et al. Biodegradable silicon nanoneedles delivering nucleic acids intracellularly induce localized in vivo neovascularization. Nature Mater. 14, 532–539 (2015).10.1038/nmat4249 ↗
50. Copp, J. A. et al. Clearance of pathological antibodies using biomimetic nanoparticles. Proc. Natl Acad. Sci. USA 111, 13481–13486 (2014).10.1073/pnas.1412420111 ↗